antiemetic Efficacy1

MARINOL Capsules are indicated for nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.

Clinical trials

Treatment of Chemotherapy-Induced Emesis:1

  • Evaluated in 454 patients with cancer, who received a total of 750 courses of treatment of various malignancies.


  • The antiemetic efficacy of MARINOL Capsules was greatest in patients receiving cytotoxic therapy with MOPP* for Hodgkin’s and non-Hodgkin’s lymphomas.
  • MARINOL Capsules dosages ranged from 2.5 mg/day to 40 mg/day, administered in equally divided doses every four to six hours (four times daily).
  • As indicated in the following table, escalating the MARINOL Capsules dose above 7 mg/m2 increased the frequency of adverse experiences, with no additional antiemetic benefit.

Safety Considerations:

Combination antiemetic therapy with MARINOL Capsules and a phenothiazine (prochlorperazine) may result in synergistic or additive antiemetic effects and attenuate the toxicities associated with each of the agents.

The pharmacologic effects of MARINOL Capsules are dose-related and subject to considerable interpatient variability. Therefore, dosage individualization is critical in achieving the maximum benefit of MARINOL Capsules treatment.

*MOPP refers to a chemotherapy combination comprised of Mustargen®, Oncovin®, procarbazine, and prednisone.2

MARINOL Capsules Dose: Response Frequency and Adverse Experiences (N=50 treatment courses)

MARINOL Capsules DoseResponse Frequency (%)Adverse Events Frequency (%)
<7 mg/m2363232236512
>7 mg/m2333136135828

Nondysphoric events consisted of drowsiness, tachycardia, etc.